STADA Arzneimittel and Alvotech announced the launch of their high-concentration, citrate-free adalimumab biosimilar (Hukyndra) in France, Germany, Finland, and Sweden, with more European countries to come.
STADA Arzneimittel and Alvotech announced the launch of their high-concentration, citrate-free adalimumab biosimilar (Hukyndra; AVT02) in France, Germany, Finland, and Sweden, with more European countries to come.
The biosimilar to Humira will be offered to patients with rheumatic conditions in a 100-mg/mL high-formulation administered in a 40-mg/0.4-mL custom-designed prefilled auto-injector pen and as a 40-mg/0.4-mL or 80-mg/0.8-mL prefilled syringe.
Hukyndra represents STADA's fifth EU-approved biosimilar, following its epoetin zeta, pegfilgrastim, teriparatide, and bevacizumab biosimilars. In addition to AVT02, Alvotech is developing an ustekinumab biosimilar representing Stelara, which has shown promise in phase 1 and phase 3 trials, and had partnered with BiosanaPharma for a biosimilar to Xolair (omalizumab).
“Although biosimilar medicines have been marketed in Europe for over 16 years, significant unmet needs exist for patients to access key therapies…. Positively impacting the lives of European patients with inflammatory disorders with our high-concentration, citrate-free alternative to Humira is fully in line with STADA’s purpose of caring for people’s health as a trusted partner,” said Bryan Kim, head of global specialty and executive vice president at STADA, in a statement.
AVT02 was granted marketing authorization in the European Union in December 2021 and has been approved in the United Kingdom, Switzerland, Norway, Iceland, Lichtenstein, and Canada. In Canada, AVT02 is marketed under the name Simlandi. Besides Hukyndra, there are 9 other EU-approved adalimumab biosimilars: Amgevita, Amsparity, Hefiya, Hulio, Hyrimoz, Idacio, Imraldi, Libmyris, and Yuflyma.
Alvotech and its commercialization partner Teva Pharmaceuticals are seeking approval for AVT02 with interchangeability status in the United States, where the biosimilar is under review.
“We are thrilled to take this important step with STADA into multiple European markets. The commercial partnership with STADA allows Alvotech to leverage its strengths as a purpose-built [research and development] and manufacturing platform, singularly focused on biosimilars, which are of vital importance for health care systems globally,” commented Anil Okay, chief commercial officer at Alvotech.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.